Vandortuzumab is a humanised monoclonal antibody targeting STEAP1, commonly used as the targeting component of the synthetic ADC (antibody-drug conjugate) vandortuzumab vedotin, and is applicable for prostate cancer research.
Purity:
95%
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
